Table A2.
Patient characteristics and treatment data of subgroup entities.
| Characteristics/Entity | Ependymoma | Low-Grade Glioma | ATRT | Medulloblastoma | Cranio-Pharyngioma | Intracranial Germ Cell Tumor | Retinoblastoma | Others |
|---|---|---|---|---|---|---|---|---|
| gender | male 36 (42.4%)/female 49 (57.6%) | male 15 (50.0%)/female 15 (50.0%) | male 18 (51.4%)/female 17 (48.6%) | male 41 (70.7%)/female 17 (29.3%) | male 11 (42.3%)/female 15 (57.7%) | male 11 (68.7%)/female 5 (31.3%) | male 8 (88.9%)/female 1 (11.1%) | male 14 (50.0%)/female 14 (50.0%) |
| age at diagnosis | median 2.4 years (range 0.1–16.9) | median 7.95 (0.2–17.0) | median 1.5 years (range 0.0–7.5 y.) | median 6.2 years (range 0.9–16.2 y.) | median 9.35 years (range 2.5–15.5 y.) | median 11.1 years (range 2.9–16.3 y.) | median 1.0 years (range 0–3.7 y.) | median 5.95 years (range 1.8–17.7 y.) |
| age at start of PBT | median 3.1 years (range 0.9–17.0) | median 11.4 (4.6–17.9) | median 1.9 years (range 1.0–8.0 y.) | median 6.5 years (range 2.0–16.5 y.) | median 10.65 years (range 5.4–17.1 y.) | median 11.5 years (range 3.3–16.6 y.) | median 2.5 years (range 1.2–8.0 y.) | median 9.0 years (range 2.1–18.0 y.) |
| resection status | ||||||||
| GTR/NTR | 50 (58.8%) | 0 | 10 (28.6%) | 34 (58.6%) | 0 | 6 (37.5%) | 0 | 12 (42.8%) |
| STR | 34 (40%) | 14 (46.7%) | 24 (68.6%) | 20 (34.5%) | 22 (84.6%) | 2 (12.5%) | 0 | 11 (39.3%) |
| none/biopsy only | 1 (1.2%) | 16 (53.3%) | 1 (2.9%) | 4 (6.9%) | 4 (15.4%) | 8 (50%) | 9 (100%) | 5 (17.9) |
| localization | ||||||||
| supratentorial | 15 (17.6%) | 25 (83.3%) | 16 (45.7%) | 0 | 26 (100%) | 16 (100%) | 9 (100%) | 21 (75%) |
| infratentorial | 70 (82.4%) | 5 (16.7%) | 19 (54.3%) | 58 (100%) | 0 | 0 | 0 | 7 (25%) |
| number of surgeries prior to PBT | median 2 (1–6) | median 1 (0–4) | median 1 (0–7) | median 1 (1–3) | median 2 (1–7) | median 1 (0–3) | 0 | median 1 (0–3) |
| metastasis prior to PBT | 5 (5.9%) | 4 (133%) | 6 (17.1%) | 18 (31.0%) | 0 | 2 (12.5%) | 1 (11.1%) | 5 (17.9%) |
| timepoint of PBT | ||||||||
| primary diagnosis | 68 (80%) | 12 (40.0%) | 33 (94.3%) | 47 (81.0%) | 3 (11.5%) | 15 (93.8%) | 4 (44.4%) | 13 (46.4%) |
| recurrence/progression | 17 (20%) | 18 (60.0%) | 2 (5.7%) | 11 (19.0%) | 23 (88.5%) | 1 (6.7%) | 5 (55.6%) | 15 (53.6%) |
| reservoir during PBT | 7 (8.2%) | 3 (10%) | 23 (65.7%) | 12 (20.7%) | 6 (23.1%) | 2 (12.5%) | 0 | 3 (10.7%) |
| VP/VA shunt during PBT | 28 (32.9%) | 6 (20.0%) | 12 (34.3%) | 13 (22.4%) | 5 (19.2%) | 0 | 0 | 2 (7.1%) |
| prior RT in overlapping area | 7 (8.2%) | 0 | 1 (2.9%) | 4 (6.9%) | 1 (3.8%) | 0 | 4 (44.4%) | 1 (3.6%) |
| prior chemotherapy | 41 (48.2%) | 16 (53.3%) | 35 (100%) | 30 (51.7%) | 0 | 16 (100%) | 8 (88.9%) | 14 (50.0%) |
| concomitant CTX | 10 (11.8%) | 1 (3.3%) | 15 (42.9%) | 55 (60.3%) | 0 | 0 | 0 | 9 (32.1%) |
| inpatient treatment besides CTX | 15 (17.6%) | 4 (13.3%) | 13 (37.1%) | 15(19.5%) | 2(7.7%) | 0 | 2 (22.2%) | 3 (10.7%) |
| anesthesia during PBT | 69 (81.2%) | 23 (76.7%) | 34 (97.1%) | 37 (63.8%) | 3 (11.5%) | 1 (6.3%) | 9 (100%) | 14 (50.0%) |
| PBT technique | ||||||||
| PBS | 35 (41.2%) | 13 (5.7%) | 17 (46.6%) | 38 (65.5%) | 18 (59.2%) | 13 (81.3%) | 4 (44.4%) | 20 (71.4%) |
| US | 45 (52.9%) | 16 (45.7%) | 16 (45.7%) | 3 (5.2%) | 8 (30.2%) | 3 (18.7%) | 5 (55.6%) | 4 (14.3%) |
| PBS and US | 5 (5.9%) | 1 (2.7%) | 2 (5.7%) | 17 (29.3%) | 0 | 0 | 0 | 4 (14.3%) |
| median dose | median 54.04 (range 49.6–62.0 Gy) | median 54.0 (range 46.0–554 Gy) | median 54.0 Gy (range 36.6–60.0 Gy) | median 54.0 Gy (range 30.0–72.0 Gy) | 54.0 Gy | 54.0 Gy (24–54 Gy) | 50.0 Gy (49,6–50,0 Gy) | 54.0 Gy (45–72,0 Gy) |
| number of fractions | median 31 (range 30–33) | median 30 (28–33) | median 30 (range 22–35) | median 30 (range 6–72) | 30 | 30 (15–30) | 30 (15–30) | 31 (25–70) |
| CSI | 2 (2.4%) | 1 (3.3%) | 6 (17.1%) | 50 (86.2%) | 0 | 2 (12.5%) | 1 (11.1%) | 8 (28.6%) |
| chemotherapy after PBT | 32 (37.9%) | 9 (24.3%) | 13 (37.1%) | 47 (81.0%) | 0 | 2 (12.5%) | 3 (33.3%) | 13 (46.4%) |
| interruption of PBT treatment > 2 days | 10 (11.8%) | 2 (6.7%) | 4 (11.4%) | 2 (3.4%) | 2 (7.7%) | 1 (6.3%) | 1 (11.1%) | 2 (7.1%) |
| Follow-up since end of PBT | median 39.7 months (3.2–83.3 m) | median 49.95 months (7.7–76.7 m) | median 34.2 months (range 0.7–76.1 m) | median 36.0 months (range 2.7–67.1 m) | median 47.9 months (range 11.7–77.5 m) | median 35.5 months (range 20.3–81.7 m) | median 38.2 months (range 3.0–52.9 m) | median 34.1 months (range 3.9–73.3 m) |
Abbreviations: PBT = proton beam therapy; GTR = gross total resection; NTR = near total resection; STR = subtotal resection; PBS = pencil beam scanning; US = uniform scanning; CTX = chemotherapy; VP = ventriculoperitoneal; VA = ventriculoatrial; CSI = craniospinal irradiation; ATRT = atypical teratoid rhabdoid tumor.